Zuellig Pharma Co Ltd 2024 SR
The report highlights Zuellig Pharma's sustainability progress and performance for the fiscal year 2024. The company achieved a 42% reduction in Scope 1 and 2 emissions and a 47% reduction in Scope 3 emissions compared to its 2021 baseline, meeting its near-term targets ahead of schedule. Additionally, Zuellig Pharma maintained its EcoVadis Platinum rating for the fourth consecutive year and received an 'A' score from CDP for climate change disclosure. The company also expanded its digital health solutions, such as eZTracker and PatientCare+, to improve healthcare accessibility and supply chain security across Asia.
Company: Zuellig Pharma Co Ltd
Year: 2024
Type: SR
Pages: 139
Zuellig Pharma Co Ltd
Sustainability Report
The report highlights Zuellig Pharma's sustainability progress and performance for the fiscal year 2024. The company achieved a 42% reduction in Scope 1 and 2 emissions and a 47% reduction in Scope 3 emissions compared to its 2021 baseline, meeting its near-term targets ahead of schedule. Additionally, Zuellig Pharma maintained its EcoVadis Platinum rating for the fourth consecutive year and received an 'A' score from CDP for climate change disclosure. The company also expanded its digital health solutions, such as eZTracker and PatientCare+, to improve healthcare accessibility and supply chain security across Asia.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees